Biotricity Inc. (BTCY): Price and Financial Metrics
GET POWR RATINGS... FREE!
BTCY Stock Price Chart Interactive Chart >
BTCY Price/Volume Stats
|Current price||$1.11||52-week high||$5.30|
|Prev. close||$1.13||52-week low||$0.95|
|Day high||$1.14||Avg. volume||132,087|
|50-day MA||$1.30||Dividend yield||N/A|
|200-day MA||$2.45||Market Cap||56.92M|
Biotricity Inc. (BTCY) Company Bio
Biotricity, Inc. is a medical technology company, which is focused on biometric data monitoring solutions. It also involves in delivering, remote monitoring solutions to the medical, healthcare, and consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. The firm’s FDA-approved Bioflux MCT technology, is comprised of a monitoring device and software components, which is made available to the market, in order to assess, establish and develop sales processes, and market dynamics. The company was founded by Waqaas Al-Siddiq and Peter McGoldrick on August 29, 2012 and is headquartered in Redwood City, CA.
Most Popular Stories View All
BTCY Latest News Stream
|Loading, please wait...|
BTCY Latest Social Stream
View Full BTCY Social Stream
Latest BTCY News From Around the Web
Below are the latest news stories about Biotricity Inc that investors may wish to consider to help them evaluate BTCY as an investment opportunity.
* Announcement follows FDA clearance * Pre-Orders begin on February 23, 2022 with units shipping April 1, 2022REDWOOD CITY, CA / ACCESSWIRE / February 23, 2022 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced that it is now taking pre-orders for Biotres, the Company's three-lead device designed to continuously record electro-cardiogram (ECG) data for early detection of cardiac arrhythmias.
Maxim Group analyst Allen Klee reiterated a Buy rating on Biotricity (BTCY – Research Report) yesterday and set a price target of $7.00. The company's shares closed last Wednesday at $2.92. According to TipRanks.com, Klee is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -19.4% and a 21.9% success rate. Klee covers the Technology sector, focusing on stocks such as Advanced Human Imaging, Digital Turbine, and Mitek Systems. Currently, the analyst consensus on Biotricity is a Moderate Buy with an average price target of $6.50, an 116.7% upside from current levels. In a report released yesterday, H.C.
There's a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Alteryx (AYX – Research Report) and Biotricity (BTCY – Research Report) with bullish sentiments. Alteryx (AYX) Rosenblatt Securities analyst Blair Abernethy maintained a Buy rating on Alteryx today and set a price target of $87.00. The company's shares closed last Tuesday at $52.19, close to its 52-week low of $49.67. According to TipRanks.
BTCY: Topline Growth Continues Despite Omicron Headwinds as the Company Expands Salesforce & Is Unleashing New Revenue Streams Soon
By T. Moore, CFA NASDAQ:BTCY READ THE FULL BTCY RESEARCH REPORT Business News Update Biotricity Inc. (NASDAQ:BTCY) reported December quarter results of 93% sales growth from the year-ago quarter. 7% sequential sales growth was held back by Omicron COVID-19 causing the delay of patient visits and some temporary closings of clinics and doctor’s offices. Simply a deferral and pushout of revenues
No summary available.
BTCY Price Returns